CN115151309A - 抗clec-1a抗体及其抗原结合片段 - Google Patents

抗clec-1a抗体及其抗原结合片段 Download PDF

Info

Publication number
CN115151309A
CN115151309A CN202080095475.7A CN202080095475A CN115151309A CN 115151309 A CN115151309 A CN 115151309A CN 202080095475 A CN202080095475 A CN 202080095475A CN 115151309 A CN115151309 A CN 115151309A
Authority
CN
China
Prior art keywords
seq
antibody
ser
clec
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095475.7A
Other languages
English (en)
Chinese (zh)
Inventor
E·希福洛
N·普瓦里耶
A·德塞勒
V·特普尼尔
C·马里
V·高铁尔
S·庞甘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute Of Health And Medical Sciences
OSE Immunotherapeutics SA
Nantes Université
Original Assignee
National Institute Of Health And Medical Sciences
Universite de Nantes
OSE Immunotherapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute Of Health And Medical Sciences, Universite de Nantes, OSE Immunotherapeutics SA filed Critical National Institute Of Health And Medical Sciences
Publication of CN115151309A publication Critical patent/CN115151309A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080095475.7A 2019-12-05 2020-12-04 抗clec-1a抗体及其抗原结合片段 Pending CN115151309A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19306583.6 2019-12-05
EP19306583 2019-12-05
PCT/EP2020/084770 WO2021110990A1 (en) 2019-12-05 2020-12-04 Anti-clec-1a antibodies and antigen-binding fragment thereof

Publications (1)

Publication Number Publication Date
CN115151309A true CN115151309A (zh) 2022-10-04

Family

ID=69232731

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095475.7A Pending CN115151309A (zh) 2019-12-05 2020-12-04 抗clec-1a抗体及其抗原结合片段

Country Status (6)

Country Link
US (1) US20230331852A1 (https=)
EP (1) EP4069372A1 (https=)
JP (1) JP2023504733A (https=)
CN (1) CN115151309A (https=)
CA (1) CA3159155A1 (https=)
WO (1) WO2021110990A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL309107A (en) * 2021-06-08 2024-02-01 Ose Immunotherapeutics Humanized antibodies against CLEC-1A, antigen-binding fragments thereof and their mimetics
CN118510534A (zh) * 2021-11-09 2024-08-16 Ose免疫疗法 Clec-1配体的识别及其用途
JP2025525884A (ja) * 2022-08-01 2025-08-07 オーエスイー・イミュノセラピューティクス ヘテロ二量体Ｆｃ－ＣＬＥＣ－１融合分子及びその使用
WO2025032213A1 (en) * 2023-08-10 2025-02-13 Ose Immunotherapeutics Identification of hla-dra as a ligand of clec-1 and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069573A (zh) * 2016-03-07 2018-12-21 弗拉芒区生物技术研究所 结合cd20的单结构域抗体
CN109789206A (zh) * 2016-09-16 2019-05-21 生态有限公司 抗体和检查点抑制剂的组合疗法
CN110291102A (zh) * 2016-10-21 2019-09-27 国立卫生和医学研究所 促进t细胞应答的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069573A (zh) * 2016-03-07 2018-12-21 弗拉芒区生物技术研究所 结合cd20的单结构域抗体
CN109789206A (zh) * 2016-09-16 2019-05-21 生态有限公司 抗体和检查点抑制剂的组合疗法
CN110291102A (zh) * 2016-10-21 2019-09-27 国立卫生和医学研究所 促进t细胞应答的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARIA DOLORES LOPEZ ROBLES ET AL.: ""Cell-surface C-type lectin-like receptor CLEC-1 dampens dendritic cell activation and downstream Th17 responses"", 《BLOOD ADVANCES》, vol. 1, no. 9, 31 December 2017 (2017-12-31), pages 557 - 568 *

Also Published As

Publication number Publication date
CA3159155A1 (en) 2021-06-10
EP4069372A1 (en) 2022-10-12
JP2023504733A (ja) 2023-02-06
WO2021110990A1 (en) 2021-06-10
US20230331852A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
CN110914296B (zh) 改造的Fc片段，包含其的抗体及其应用
CN109476746B (zh) Egfr结合分子
CN108779175B (zh) NKp46结合蛋白的可变区
AU2015279316B2 (en) Multispecific NKp46 binding proteins
TWI688572B (zh) 包含dr5-結合結構域的多價分子
CN113423733A (zh) 结合tslp的抗体及其用途
WO2020043184A1 (zh) 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN111819198A (zh) 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
CN115151309A (zh) 抗clec-1a抗体及其抗原结合片段
AU2016284871A1 (en) Multispecific NK engager proteins
KR20180040138A (ko) 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
KR102920224B1 (ko) 인간화 항-VEGF Fab 항체 단편 및 이의 용도
KR102820082B1 (ko) 항-her2/항-4-1bb 이중 특이 항체 및 이의 용도
CN106795223B (zh) 针对Fcγ受体IIB及Fcε受体的抗体
CN108659112B (zh) 一种非对称双特异性抗体
KR20240019218A (ko) T 세포 관여자 분자 및 이의 용도
CN113583127A (zh) 一种靶向nkg2a和pd-l1的双特异性抗体及应用
KR102920217B1 (ko) 인간화 항-vegf 단클론 항체
CN114685660A (zh) 抗cldn18.2抗体及其制备方法和应用
KR20210068065A (ko) 안타고니스트
CN117355540A (zh) 抗cd137抗体和使用方法
AU2021224787A1 (en) CD137 binding molecules and uses thereof
AU2022290831B2 (en) Humanized anti-clec-1a antibodies and antigen-binding fragments thereof and mimetics thereof
TW202434644A (zh) 三特異性抗原結合分子及其應用
RU2802960C2 (ru) Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination